Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001
- PMID: 19257816
- DOI: 10.1359/jbmr.090207
Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001
Abstract
In patients with prior hip fracture (HFx), little is known about time frame and risk factors of second HFx, as well as the ensuing mortality. The aim of the study was to elucidate the incidence of second HFx and subsequent mortality. All 169,145 patients with a first HFx in Denmark during 1977-2001 were followed for up to 25 yr and compared with the background population. Data on fractures, vital status, comorbidity, redeemed prescriptions, and socio-demographic variables were retrieved from national registers. Median follow-up was 3.8 yr, corresponding to 1,041,177 patient-years. A total of 27,834 patients had a second HFx. The cumulative incidence was 9% after 1 yr and 20% after 5 yr, being significantly higher than expected (2% and 12%, respectively; p < 0.05). The RR of second HFx was 2.2 (95% CI: 2.0-2.5) at 1 yr and did not normalize until 15 yr (RR = 1.01, 95% CI: 1.0-1.02). Risk factors for a second HFx were female sex (HR = 1.36, 95% CI: 1.32-1.40), age (HR = 1.68, 95% CI: 1.60-1.76 in patients >85 yr), alcoholism (HR = 1.61, 95% CI: 1.51-1.72), any prior fracture (HR = 1.08, 95%CI :1.04-1.11), and living alone (HR = 1.06, 95% CI: 1.04-1.09). Both sexes had higher mortality at 1 and 5 yr after a second HFx compared with the background population (men-1 yr: 27% versus 9%, p < 0.05; 5 yr: 64% versus 40%, p < 0.05; women-1 yr: 21% versus 10%, p < 0.05; 5 yr: 58% versus 41%, p < 0.05). Patients with HFx are at 2-fold risk of further HFx and the subsequent mortality is highly increased. We propose that programs for secondary prevention should be developed and tested.
Similar articles
-
Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival.Age Ageing. 2010 Mar;39(2):203-9. doi: 10.1093/ageing/afp221. Epub 2010 Jan 14. Age Ageing. 2010. PMID: 20075035
-
Adjusted mortality after hip fracture: From the cardiovascular health study.J Am Geriatr Soc. 2006 Dec;54(12):1885-91. doi: 10.1111/j.1532-5415.2006.00985.x. J Am Geriatr Soc. 2006. PMID: 17198494
-
Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures.J Bone Miner Res. 2005 Mar;20(3):494-500. doi: 10.1359/JBMR.041133. Epub 2004 Nov 29. J Bone Miner Res. 2005. PMID: 15746995
-
Mortality rates of patients with a hip fracture in a southwestern district of Greece: ten-year follow-up with reference to the type of fracture.Calcif Tissue Int. 2006 Feb;78(2):72-7. doi: 10.1007/s00223-005-0169-6. Epub 2006 Feb 6. Calcif Tissue Int. 2006. PMID: 16467975
-
Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study.Osteoporos Int. 2006;17(9):1353-7. doi: 10.1007/s00198-006-0125-y. Epub 2006 Jul 6. Osteoporos Int. 2006. PMID: 16823545 Review.
Cited by
-
Accuracy of evidence-based criteria for identifying an incident hip fracture in the absence of the date of injury: a retrospective database study.BMJ Open. 2013 Jul 17;3(7):e003222. doi: 10.1136/bmjopen-2013-003222. Print 2013. BMJ Open. 2013. PMID: 23869105 Free PMC article.
-
Reoperation and revision rates at ten years after 1,312 cemented Thompson's hemiarthroplasties : any need to change to a different implant?Bone Jt Open. 2022 Sep;3(9):710-715. doi: 10.1302/2633-1462.39.BJO-2022-0084. Bone Jt Open. 2022. PMID: 36062890 Free PMC article.
-
Using vital statistics to estimate the population-level impact of osteoporotic fractures on mortality based on death certificates, with an application to France (2000-2004).BMC Public Health. 2009 Sep 17;9:344. doi: 10.1186/1471-2458-9-344. BMC Public Health. 2009. PMID: 19761614 Free PMC article.
-
The definition and clinical significance of nonvertebral fractures.Curr Osteoporos Rep. 2010 Dec;8(4):227-34. doi: 10.1007/s11914-010-0030-3. Curr Osteoporos Rep. 2010. PMID: 20811964 Review.
-
Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.Arch Osteoporos. 2019 Jun 5;14(1):59. doi: 10.1007/s11657-019-0608-z. Arch Osteoporos. 2019. PMID: 31168657 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical